Related Experiment Video

Updated: May 15, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Mutants of lymphotoxin-α with augmented cytotoxic activity via TNFR1 for use in cancer therapy

Tomohiro Morishige1, Yasuo Yoshioka, Shogo Narimatsu

  • 1Laboratory of Biotechnology and Therapeutics, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan.

Cytokine
|December 19, 2012
PubMed

Insights

Researchers engineered a lymphotoxin-α (LTα) mutant with significantly enhanced tumor necrosis factor receptor 1 (TNFR1) bioactivity for improved cancer therapy. This optimized LTα mutant shows greater potential for targeted cancer treatment by selectively activating TNFR1 pathways.

Area of Science:

  • Biochemistry
  • Immunology
  • Molecular Biology

Background:

  • Lymphotoxin-α (LTα) shows promise for cancer therapy but suffers from in vivo instability and low tumor necrosis factor receptor 1 (TNFR1)-mediated bioactivity.
  • Limited therapeutic efficacy of wild-type LTα necessitates the development of enhanced variants.

Purpose of the Study:

  • To engineer LTα mutants with substantially increased TNFR1-mediated bioactivity for improved cancer treatment applications.
  • To investigate the binding kinetics and signal transduction properties of engineered LTα mutants.

Main Methods:

  • Phage display technique was employed to create a library of lysine-deficient LTα structural variants with randomized amino acid residues.
  • Affinity panning and screening were performed to identify LTα mutants with enhanced TNFR1 binding and bioactivity.
  • Comparative analysis of TNFR1 and TNFR2-mediated bioactivity, caspase activation, and nuclear factor-kappa B (NF-κB) signaling was conducted.

Main Results:

  • A novel LTα mutant was identified with 32-fold greater TNFR1-mediated bioactivity compared to wild-type LTα (wtLTα).
  • The enhanced bioactivity resulted from augmented affinity to TNFR1, primarily due to slower dissociation kinetics.
  • The LTα mutant demonstrated potent and rapid caspase activation, crucial for TNFR1-mediated cell death, with similar NF-κB activation to wtLTα.

Conclusions:

  • The binding kinetics of LTα to TNFR1 significantly influence signal transduction pathways.
  • A TNFR1-selective LTα mutant with augmented bioactivity represents a promising candidate for advanced cancer therapy.
  • Engineering LTα for enhanced TNFR1 selectivity and potency offers a viable strategy to overcome therapeutic limitations.

More Related Videos

Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody (mAb) by Neutralizing TNF Using an In Vitro Bioanalytical Method16:07

Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody (mAb) by Neutralizing TNF Using an In Vitro Bioanalytical Method

Published on: September 16, 2017

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...